Rx Studio

Precision medicine is one of the most promising frontiers of medicine, but most health systems have failed to embrace it at the strategic level. The result has been promising yet inconsistent adoption and a failure to capture its true value and transformative potential. For health system leaders, the time to embrace a coordinated enterprise precision medicine strategy is now.

ActX helps physicians make better decisions about medical treatment, using patients’ genetic information. Integrated into the Electronic Health Record (EHR) and normal workflow, ActX analyzes the patient’s genetic information in real time and alerts clinicians about drug-genome interactions, actionable hereditary risks and other important genetic risk factors. ActX has been successfully adopted by many of the country’s leading health systems, both academic and community based. With ActX, health systems can provide system-wide, EHR integrated, precision medicine with rapid implementation. ActX provides comprehensive actionable content, evidence based and frequently updated, coupled with the flexibility of customization. Genetic data can be easily imported from any clinically valid source, internal or external. ActX is workflow and provider friendly, integrating seamlessly with the leading EHR’s.

With decades of pioneering proteomics expertise, SomaLogic delivers a comprehensive protein detection technology to expose early biologic signs that a patient may be headed for a severe health event, revealing whether existing treatments are adequately reducing risk or if adaptations are needed. Because proteins are constantly changing, they provide better and more actionable insights on patient health risks and propensity for disease. Unlike SomaLogic solutions, most current tools are not prognostic in nature and can’t be used to determine future health risk–they’re mostly used to confirm whether a person has elevated risk. These approaches are also not responsive to change over time, which makes it difficult to understand if existing treatments are effective and to track disease trajectory.

CancerIQ is solving three main access problems related to starting, running and growing a cancer genetics program: Identification. Because gathering family history can be time-consuming and laborious, providers often skip this step altogether, leaving patient genetic risk remains unknown. CancerIQ’s platform digitally collects family and lifestyle history and automatically identifies and flags patients who qualify for genetic testing based on the newest industry guidelines. Clinical guidance. It’s difficult to interpret genetic tests and personalize patient care because most providers do not have extensive genetics training and guidelines change on a regular basis. CancerIQ automatically generates care plan recommendations and guides shared decision-making and patient activation at the point of care. Follow-through. Without the proper education and engagement, patients don’t adhere to personalized care recommendations and programs don’t generate the clinical and financial return on investment they expect. CancerIQ provides the tools and technology that health systems need in order to engage and manage high-risk patients over time and improve long-term outcomes.

Pharmacogenomics, also called precision prescribing or referred to with the shorthand PGx, is the ability to use a network of knowledge to treat an individual patient by analyzing genetic information in combination with social, environmental and lifestyle factors. Digital pharmacogenomic solutions provide clinicians–most commonly in primary care, cardiology, behavioral health or oncology service lines–with targeted genomic testing and automated clinical decision support that analyzes all relevant data to deliver optimized drug and dosage recommendations. With medication regimens tailored to their drug metabolism and other health variables, patients are more likely to receive safe and effective medications the first time while avoiding drug failure or adverse reactions.